2-mercaptobenzoxazole profile

ID Source	ID
PubMed CID	712377
CHEMBL ID	113414
CHEBI ID	190968
SCHEMBL ID	9430874
SCHEMBL ID	57538
MeSH ID	M0517222

Synonym
AC-4802
HMS2602L19
2382-96-9
2-benzoxazolinethione
2(3h)-benzoxazolethione
benzoxazolinethione
2-benzoxazolethiol
nsc-2128
2-mercaptobenzoxazole ,
benzoxazole, 2-mercapto-
nsc2128
2-mercapto-1,3-benzoxazole
smr000337568
MLS000696385
1,3-benzoxazol-2-ylhydrosulfide
2-benzoxazolylthiol
2-benzoxazolethione
ai3-18637
einecs 219-191-9
nsc 209084
benzoxazole-2-thiol
nsc 2128
nsc209084
3h-1,3-benzoxazole-2-thione
nsc-209084
benzoxazoline,2-thione
inchi=1/c7h5nos/c10-7-8-5-3-1-2-4-6(5)9-7/h1-4h,(h,8,10
1,3-benzoxazole-2(3h)-thione
2-mercaptobenzoxazole, 95%
1,3-benzoxazole-2-thiol
STK387533
B0096
benzooxazole-2-thiol
CHEMBL113414 ,
SCHEMBL9430874
AKOS002268882
CHEBI:190968
AKOS000119127
NCGC00246572-01
benzoxazole-2-thione
unii-7pfu48rafx
7pfu48rafx ,
A816929
118090-08-7
FT-0612760
MS-3157
2-mercapto benzoxazole
SCHEMBL57538
benzo[d]oxazole-2-thiol
2-mercapto-1h-benzoxazole
2-mercaptobenzooxazole
DTXSID8062363
benzoxazoline-2-thione
J-650292
W-202001
2,3-dihydro-1,3-benzoxazole-2-thione
STR03785
2-thio-1,3-benzoxazole
benzoxazolethiol
mfcd00005769
F0777-0783
SY048415
CS-W018116
Q17310064
AM10745
benzo[d]oxazole-2(3h)-thione
EN300-21478
mercaptobenzoxazole
p92 ,
3~{h}-1,3-benzoxazole-2-thione
bdbm50570938
Z104499134

Class	Description
benzoxazole	Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	35.4813	0.1778	14.3909	39.8107	AID2147
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	79.4328	0.1000	20.8793	79.4328	AID588453
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	28.1838	0.0112	12.4002	100.0000	AID1030
lysosomal alpha-glucosidase preproprotein	Homo sapiens (human)	Potency	7.0795	0.0366	19.6376	50.1187	AID1466; AID2242
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	100.0000	5.8048	36.1306	65.1308	AID540263
snurportin-1	Homo sapiens (human)	Potency	100.0000	5.8048	36.1306	65.1308	AID540263
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	28.1838	0.0079	8.2332	1,122.0200	AID2551
Neuronal acetylcholine receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	7.0795	3.5481	18.0395	35.4813	AID1466
Neuronal acetylcholine receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	7.0795	3.5481	18.0395	35.4813	AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Proteasome subunit beta type-8	Homo sapiens (human)	IC50 (µMol)	17.0000	0.0013	0.3698	5.0000	AID1763210
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Process	via Protein(s)	Taxonomy
antigen processing and presentation	Proteasome subunit beta type-8	Homo sapiens (human)
fat cell differentiation	Proteasome subunit beta type-8	Homo sapiens (human)
regulation of endopeptidase activity	Proteasome subunit beta type-8	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Proteasome subunit beta type-8	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Process	via Protein(s)	Taxonomy
threonine-type endopeptidase activity	Proteasome subunit beta type-8	Homo sapiens (human)
protein binding	Proteasome subunit beta type-8	Homo sapiens (human)
endopeptidase activity	Proteasome subunit beta type-8	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Process	via Protein(s)	Taxonomy
nucleoplasm	Proteasome subunit beta type-8	Homo sapiens (human)
cytosol	Proteasome subunit beta type-8	Homo sapiens (human)
extracellular exosome	Proteasome subunit beta type-8	Homo sapiens (human)
proteasome complex	Proteasome subunit beta type-8	Homo sapiens (human)
proteasome core complex	Proteasome subunit beta type-8	Homo sapiens (human)
proteasome core complex, beta-subunit complex	Proteasome subunit beta type-8	Homo sapiens (human)
spermatoproteasome complex	Proteasome subunit beta type-8	Homo sapiens (human)
nucleus	Proteasome subunit beta type-8	Homo sapiens (human)
cytosol	Proteasome subunit beta type-8	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID373119	Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 14 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID1763213	Glutathione reactivity of compound measured after 24 hrs by NMR based assay	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Discovery of selective fragment-sized immunoproteasome inhibitors.
AID614050	Inhibition of bovine testes hyaluronidase at 200 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID1721328	Substrate-dependent activation of HDAC8 (unknown origin) assessed as fold activation using FLUOR DE LYS as substrate at 20 uM incubated for 30 mins by fluorescence based assay relative to control	2020	Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16	An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators.
AID373114	Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 14 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID144148	In vitro inhibition of Mycobacterium Kansasi (My 235/80) growth after 21 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID145146	In vitro inhibition of Mycobacterium Tuberculosis (My 331/88) growth after 21 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID614063	Inhibition of bovine testes hyaluronidase at 80 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID144147	In vitro inhibition of Mycobacterium Kansasi (My 235/80) growth after 14 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID373112	Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 21 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID373117	Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID1763224	Thiol reactivity of the compound assessed as TNB2-depletion at 200 uM measured upto 24 hrs by TNB2-depletion assay	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Discovery of selective fragment-sized immunoproteasome inhibitors.
AID614057	Inhibition of bovine testes hyaluronidase at 170 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614054	Inhibition of bovine testes hyaluronidase at 460 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614052	Inhibition of bovine testes hyaluronidase at 49 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID373111	Antimycobacterial activity against Mycobacterium tuberculosis CNCTC My 331/88 after 14 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID144149	In vitro inhibition of Mycobacterium Kansasi (My 235/80) growth after 7 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID614065	Inhibition of bovine testes hyaluronidase at 150 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614062	Inhibition of bovine testes hyaluronidase at 63 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614024	Aqueous solubility of the compound in water	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID145145	In vitro inhibition of Mycobacterium Tuberculosis (My 331/88) growth after 14 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID373116	Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID614059	Inhibition of bovine testes hyaluronidase at 400 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614055	Inhibition of bovine testes hyaluronidase at 180 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID373118	Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID614056	Inhibition of bovine testes hyaluronidase at 190 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614064	Inhibition of bovine testes hyaluronidase at 2000 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID1763210	Inhibition of human chymotrypsin-like beta 5i subunit of iCP using suc-LLVY-AMC as flurogenic substrate for 90 mins by fluorescence-based assay	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Discovery of selective fragment-sized immunoproteasome inhibitors.
AID143722	In vitro inhibition of Mycobacterium Avium growth after 14 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID373115	Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 21 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID144150	In vitro inhibition of Mycobacterium Kansasi (My 6 509/96) growth after 14 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID614038	Inhibition of Streptococcus agalactiae 4755 hyaluronidase at 3800 uM after 30 mins at pH 5.0 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614053	Inhibition of bovine testes hyaluronidase at 4200 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614061	Inhibition of bovine testes hyaluronidase at 130 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID144152	In vitro inhibition of Mycobacterium Kansasi (My 6 509/96) growth after 7 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID373120	Antimycobacterial activity against Mycobacterium avium CNCTC My 330/88 after 21 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID144151	In vitro inhibition of Mycobacterium Kansasi (My 6 509/96) growth after 21 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID614051	Inhibition of bovine testes hyaluronidase at 380 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614044	Inhibition of Streptococcus agalactiae 4755 hyaluronidase at pH 7.4 after 3 hrs by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID143841	In vitro inhibition of Mycobacterium Avium (My 330/88) growth after 21 days culture.	2002	Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.
AID373113	Antimycobacterial activity against Mycobacterium kansasii CNCTC My 235/80 after 7 days by micromethod	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
AID614060	Inhibition of bovine testes hyaluronidase at 3800 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID614058	Inhibition of bovine testes hyaluronidase at 100 uM after 30 mins at pH 5 by turbidimetric analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
AID1763219	Inhibition of beta 5 chymotrypsin-like activity (unknown origin) at 100 uM using Suc-LLVY-AMC as substrate for 90 mins by fluorescence based assay	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Discovery of selective fragment-sized immunoproteasome inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (35.00)	29.6817
2010's	8 (40.00)	24.3611
2020's	5 (25.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
oxyquinoline Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.	2.25	1	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	2.43	2	carbohydrazide	antitubercular agent; drug allergen
2-thiosalicylic acid 2-thiosalicylic acid: a degradation product of thimerosal; RN given refers to parent cpd. thiosalicylic acid : A sulfanylbenzoic acid that is the 2-sulfanyl derivative of benzoic acid.	2.25	1	sulfanylbenzoic acid	antipyretic; non-narcotic analgesic
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	8.68	9	1,3-benzoxazoles; mancude organic heterobicyclic parent
glycyrrhetinic acid [no description available]	2.06	1	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
5-methylbenzimidazole 5-methylbenzimidazole: structure in first source. 5-methyl-1H-benzimidazole : A member of the class of imidazoles that is 1H-benzimidazole in which the hydrogen at position 5 is substituted by a methyl group.	7.41	1	imidazoles
zinc oxide Zinc Oxide: A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.	2.05	1	zinc molecular entity
2-(2-hydroxyphenyl)benzothiazole 2-(1,3-benzothiazol-2-yl)phenol : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by a 2-hydroxyphenyl group at position 2.	2.25	1	benzothiazoles; phenols	geroprotector
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	2.17	1	elemental platinum; nickel group element atom; platinum group metal atom
silver Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.	7.73	3	copper group element atom; elemental silver	Escherichia coli metabolite
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.17	1	copper group element atom; elemental gold
2-amino-3-hydroxypyridine [no description available]	2.25	1	aminopyridine; monohydroxypyridine
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	7.1	1	1,2,3-triazole
methylsulfonyl benzothiazole methylsulfonyl benzothiazole: structure in first source	2.31	1
2-[(4-nitrophenyl)methylthio]-1,3-benzoxazole [no description available]	2.43	2	benzoxazole
2-[(2-nitrophenyl)methylthio]-1,3-benzoxazole [no description available]	2.43	2	benzoxazole
2-cyanobenzothiazole 2-cyanobenzothiazole: structure in first source	2.31	1
2-mercaptonicotinic acid 2-mercaptonicotinic acid: structure given in first source	2.25	1
captax captax: RN given refers to parent cpd. 1,3-benzothiazole-2-thiol : 1,3-Benzothiazole substituted at the 2-position with a sulfanyl group.	3.46	7	aryl thiol; benzothiazoles	carcinogenic agent; metabolite
2-mercaptobenzimidazole 2-mercaptobenzimidazole: purine synthesis antimetabolite; RN given refers to parent cpd	8.06	4
6-amino-2-mercaptobenzothiazole [no description available]	2.31	1
5-chloro-1h-benzimidazole-2-thiol 5-chloro-1H-benzimidazole-2-thiol: trypanocidal	2.31	1
ethylenethiourea Ethylenethiourea: A degradation product of ethylenebis(dithiocarbamate) fungicides. It has been found to be carcinogenic and to cause THYROID hyperplasia.	2.41	1	imidazolidines
5-chloro-2-mercaptobenzothiazole [no description available]	2.31	1
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.06	1	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
6-o-palmitoylascorbic acid [no description available]	2.06	1	fatty acid ester

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.48	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.48	2
Leishmaniasis, American [description not available]	2.17	1
Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.	2.17	1
Anasarca [description not available]	2.1	1
Ache [description not available]	2.1	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.1	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.1	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.03	1

2-mercaptobenzoxazole

Cross-References

Synonyms (72)

Drug Classes (1)

Protein Targets (10)

Potency Measurements

Inhibition Measurements

Biological Processes (4)

Molecular Functions (3)

Ceullar Components (8)

Bioassays (56)

Research

Studies (20)

Market Indicators

Research Demand Index: 29.08

Study Types

2-mercaptobenzoxazole

Cross-References

Synonyms (72)

Drug Classes (1)

Protein Targets (10)

Potency Measurements

Inhibition Measurements

Biological Processes (4)

Molecular Functions (3)

Ceullar Components (8)

Bioassays (56)

Research

Studies (20)

Market Indicators

Research Demand Index: 29.08

Study Types

Related Drugs (26)

Related Conditions (9)